<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850030</url>
  </required_header>
  <id_info>
    <org_study_id>M13-563</org_study_id>
    <secondary_id>2012-002215-26</secondary_id>
    <nct_id>NCT01850030</nct_id>
  </id_info>
  <brief_title>A Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization</brief_title>
  <acronym>Lotus I</acronym>
  <official_title>A Double-Blind, Double-Dummy, Randomized, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization (Lotus I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Female inability to conceive a child. The purpose of this randomized, two-arm and double
      blind, double dummy study is to demonstrate that the treatment of a daily dose of 3x10mg
      dydrogesterone orally is as effective and safe as the daily dose of 3x200 mg micronized
      progesterone capsules administered intravaginally for the luteal support in patients
      undergoing IVF. The treatment will start on the day of oocyte retrieval and continue until
      pregnancy is negative or until week 12 gestation.Patients will be followed after treatment
      until 30 days after delivery to record any safety and tolerability data of the patient and
      their newborn(s).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Being Pregnant as Measured by the Presence of Fetal Heart Beats at 12 Weeks´Gestation Using Transvaginal Ultrasound</measure>
    <time_frame>12 weeks´ gestation (at visit 6)</time_frame>
    <description>Percentage of participants being pregnant as measured by the presence of fetal heart beats at 12 weeks´gestation using transvaginal ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Being Pregnant as Measured by the Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer</measure>
    <time_frame>Day 14 after embryo transfer</time_frame>
    <description>Percentage of participants being pregnant as measured by the positive biochemical pregnancy test on Day 14 after embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Successful Completion of Pregnancy</measure>
    <time_frame>After delivery (about 9 months after IVF)</time_frame>
    <description>Incidence of live births and healthy newborns</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gender of the Newborn</measure>
    <time_frame>After delivery (about 9 months after IVF)</time_frame>
    <description>was recorded and collected for Newborn</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1070</enrollment>
  <condition>Female Infertility</condition>
  <arm_group>
    <arm_group_label>Dydrogesterone 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Micronized Progesterone 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone 30 mg</intervention_name>
    <description>Oral Dydrogesterone 10 mg tablets tid</description>
    <arm_group_label>Dydrogesterone 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronized Progesterone 600 mg</intervention_name>
    <description>Intravaginal micronized progesterone 200 mg capsules tid</description>
    <arm_group_label>Micronized Progesterone 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo progesterone</intervention_name>
    <description>Placebo intravaginal micronized progesterone 200 mg capsules tid</description>
    <arm_group_label>Dydrogesterone 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo dydrogesterone</intervention_name>
    <description>placebo oral dydrogesterone 10 mg tablets tid</description>
    <arm_group_label>Micronized Progesterone 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Premenopausal females, age &gt; 18 years &lt; 42 years

          -  Non-smokers. For females who were past smokers, they must have stopped tobacco usage
             for at least 3 months prior baseline visit

          -  Early follicular phase (Day 2-4) Follicle stimulating hormone (FSH) less than or equal
             to 15 IU/L and estradiol (E2)within normal limits

          -  Luteinizing hormone (LH), prolactin (PRL), T (testosterone) and thyroid-stimulating
             hormone (TSH), within the normal limits for the clinical laboratory, or considered not
             clinically significant by the Investigator within 6 months prior to screening

          -  Documented history of infertility (e.g., unable to conceive for at least one year or
             for 6 months for women ≥ 38 years of age or bilateral tubal occlusion or absence)

          -  Normal transvaginal ultrasound at screening (or within 14 days of screening) without
             evidence of clinically significant abnormality consistent with finding adequate for
             Assisted Reproductive Technology (ART) with respect to uterus and adnexa (no
             hydrosalpinx or clinically relevant uterine fibroids)

          -  Negative pregnancy test on the day of pituitary down regulation (prior to
             administration of gonadotropin releasing hormones (GnRH) agonist or GnRH antagonist)

          -  Clinically indicated protocol for induction of IVF with a fresh embryo

          -  Single or dual embryo transfer

          -  BMI ≥ 18 and ≤ 30 kg/m2

        Exclusion Criteria:

          -  Evidence of cardiovascular, respiratory, urogenital, gastrointestinal/hepatic,
             hematologic/immunologic, head, ears, eyes, nose, throat (HEENT),
             dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, endocrine,
             neurologic/psychiatric, allergy, recent major surgery (&lt; 3 months), or other relevant
             diseases as revealed by history, physical examination and/or laboratory assessments
             which could limit participation in or completion of the study

          -  Acute urogenital disease

          -  Known allergic reactions to progesterone products

          -  Known allergic reactions to peanuts and peanut oil

          -  Intake of experimental drug or participation in any other clinical trial within 30
             days prior to study start

          -  Mental disability or any other lack of fitness, in the Investigator's opinion, to
             preclude subjects to participate in or to complete the study

          -  Current or recent substance abuse, including alcohol and tobacco (Note: Patients who
             stopped tobacco usage at least 3 months prior to screening visit would be allowed)

          -  History of chemotherapy or radiotherapy

          -  Patients with more than 3 unsuccessful IVF attempts

          -  Contraindication for pregnancy

          -  Refusal or inability to comply with the requirements of the study protocol for any
             reason, including scheduled clinic visits and laboratory tests

          -  History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darline Cheatham-Seitz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site reference no. 113176</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93593</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93598</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93615</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93617</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93613</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93594</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93597</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93616</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93595</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93614</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000884</name>
      <address>
        <city>Helsinki</city>
        <zip>00180</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000885</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000635</name>
      <address>
        <city>Oulu</city>
        <zip>90014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000795</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000633</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000645</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000643</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000642</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000644</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000883</name>
      <address>
        <city>Luebeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93635</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000934</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000935</name>
      <address>
        <city>Haifa</city>
        <zip>3339419</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93638</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 93641</name>
      <address>
        <city>Tel Aviv</city>
        <zip>69710</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Ural SRI of Maternity and Child Protection&quot; of MoH and SD</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Family Medicine LC</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGBU Endocrinology Research Center of Minzdrav of Russia</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Medical Dentistry University</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CJSC &quot;Nasledniki&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>119192</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Medical Dentistry University</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEIHPE - NWSMU n.a.l.l.Melnichko MoH and SD of RF</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg SBHI &quot;Maternity Hospital No 17&quot; (main address)</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192174</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. 119915</name>
      <address>
        <city>Baracaldo, Vizcaya</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference ID ORG-000791</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000639</name>
      <address>
        <city>Bilbao</city>
        <zip>48940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000640</name>
      <address>
        <city>Pozuelo de Alarcon (Madrid)</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000638</name>
      <address>
        <city>Sevilla</city>
        <zip>41011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site reference no. ORG-000637</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2013</study_first_submitted>
  <study_first_submitted_qc>May 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <results_first_submitted>March 8, 2017</results_first_submitted>
  <results_first_submitted_qc>May 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2018</results_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1070 subjects were enrolled in the study and 1031 subjects were randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dydrogesterone 30 mg</title>
          <description>Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid
Placebo progesterone: Placebo intravaginal micronized progesterone 200 mg capsules tid</description>
        </group>
        <group group_id="P2">
          <title>Micronized Progesterone 600 mg</title>
          <description>Micronized Progesterone 600 mg: Intravaginal micronized progesterone 200 mg capsules tid
Placebo dydrogesterone: placebo oral dydrogesterone 10 mg tablets tid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="520"/>
                <participants group_id="P2" count="511"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="347"/>
                <participants group_id="P2" count="369"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>pregnancy not confirmed at visit 4</title>
              <participants_list>
                <participants group_id="P1" count="248"/>
                <participants group_id="P2" count="249"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The full analysis sample was used here which consists of all subjects that received at least one administration of study drug and had a successful embryo transfer performed at Visit 3 (Day 3 to 6) or did not prematurely discontinue prior to embryo transfer at Visit 3 (Day 3 to 6) due to non-study drug-related issues.</population>
      <group_list>
        <group group_id="B1">
          <title>Dydrogesterone 30 mg</title>
          <description>Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid
Placebo progesterone: Placebo intravaginal micronized progesterone 200 mg capsules tid</description>
        </group>
        <group group_id="B2">
          <title>Micronized Progesterone 600 mg</title>
          <description>Micronized Progesterone 600 mg: Intravaginal micronized progesterone 200 mg capsules tid
Placebo dydrogesterone: placebo oral dydrogesterone 10 mg tablets tid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="497"/>
            <count group_id="B2" value="477"/>
            <count group_id="B3" value="974"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="497"/>
                    <measurement group_id="B2" value="477"/>
                    <measurement group_id="B3" value="974"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="4.5"/>
                    <measurement group_id="B2" value="32.5" spread="4.4"/>
                    <measurement group_id="B3" value="32.5" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="497"/>
                    <measurement group_id="B2" value="477"/>
                    <measurement group_id="B3" value="974"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Being Pregnant as Measured by the Presence of Fetal Heart Beats at 12 Weeks´Gestation Using Transvaginal Ultrasound</title>
        <description>Percentage of participants being pregnant as measured by the presence of fetal heart beats at 12 weeks´gestation using transvaginal ultrasound</description>
        <time_frame>12 weeks´ gestation (at visit 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dydrogesterone 30 mg</title>
            <description>Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid
Placebo progesterone: Placebo intravaginal micronized progesterone 200 mg capsules tid</description>
          </group>
          <group group_id="O2">
            <title>Micronized Progesterone 600 mg</title>
            <description>Micronized Progesterone 600 mg: Intravaginal micronized progesterone 200 mg capsules tid
Placebo dydrogesterone: placebo oral dydrogesterone 10 mg tablets tid</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Being Pregnant as Measured by the Presence of Fetal Heart Beats at 12 Weeks´Gestation Using Transvaginal Ultrasound</title>
          <description>Percentage of participants being pregnant as measured by the presence of fetal heart beats at 12 weeks´gestation using transvaginal ultrasound</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="497"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" lower_limit="33.4" upper_limit="42.1"/>
                    <measurement group_id="O2" value="33.1" lower_limit="28.9" upper_limit="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Being Pregnant as Measured by the Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer</title>
        <description>Percentage of participants being pregnant as measured by the positive biochemical pregnancy test on Day 14 after embryo transfer</description>
        <time_frame>Day 14 after embryo transfer</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dydrogesterone 30 mg</title>
            <description>Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid
Placebo progesterone: Placebo intravaginal micronized progesterone 200 mg capsules tid</description>
          </group>
          <group group_id="O2">
            <title>Micronized Progesterone 600 mg</title>
            <description>Micronized Progesterone 600 mg: Intravaginal micronized progesterone 200 mg capsules tid
Placebo dydrogesterone: placebo oral dydrogesterone 10 mg tablets tid</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Being Pregnant as Measured by the Positive Biochemical Pregnancy Test on Day 14 After Embryo Transfer</title>
          <description>Percentage of participants being pregnant as measured by the positive biochemical pregnancy test on Day 14 after embryo transfer</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="497"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1" lower_limit="42.6" upper_limit="51.6"/>
                    <measurement group_id="O2" value="45.5" lower_limit="41.0" upper_limit="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Successful Completion of Pregnancy</title>
        <description>Incidence of live births and healthy newborns</description>
        <time_frame>After delivery (about 9 months after IVF)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dydrogesterone 30 mg</title>
            <description>Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid
Placebo progesterone: Placebo intravaginal micronized progesterone 200 mg capsules tid</description>
          </group>
          <group group_id="O2">
            <title>Micronized Progesterone 600 mg</title>
            <description>Micronized Progesterone 600 mg: Intravaginal micronized progesterone 200 mg capsules tid
Placebo dydrogesterone: placebo oral dydrogesterone 10 mg tablets tid</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Successful Completion of Pregnancy</title>
          <description>Incidence of live births and healthy newborns</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="497"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Live birth rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" lower_limit="30.4" upper_limit="39.0"/>
                    <measurement group_id="O2" value="29.8" lower_limit="25.7" upper_limit="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Healthy newborn rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="27.9" upper_limit="36.3"/>
                    <measurement group_id="O2" value="27.7" lower_limit="23.7" upper_limit="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gender of the Newborn</title>
        <description>was recorded and collected for Newborn</description>
        <time_frame>After delivery (about 9 months after IVF)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dydrogesterone 30 mg</title>
            <description>Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid
Placebo progesterone: Placebo intravaginal micronized progesterone 200 mg capsules tid</description>
          </group>
          <group group_id="O2">
            <title>Micronized Progesterone 600 mg</title>
            <description>Micronized Progesterone 600 mg: Intravaginal micronized progesterone 200 mg capsules tid
Placebo dydrogesterone: placebo oral dydrogesterone 10 mg tablets tid</description>
          </group>
        </group_list>
        <measure>
          <title>Gender of the Newborn</title>
          <description>was recorded and collected for Newborn</description>
          <units>number of newborns</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gender male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>For Adverse Events reporting the safety sample was used consisting of all subjects which have received at least one administration of study drug (518 subjects in Dydrogesterone, 511 subjects in Micronized Progesterone)</desc>
      <group_list>
        <group group_id="E1">
          <title>Dydrogesterone 30 mg</title>
          <description>Dydrogesterone 30 mg: Oral Dydrogesterone 10 mg tablets tid
Placebo progesterone: Placebo intravaginal micronized progesterone 200 mg capsules tid</description>
        </group>
        <group group_id="E2">
          <title>Micronized Progesterone 600 mg</title>
          <description>Micronized Progesterone 600 mg: Intravaginal micronized progesterone 200 mg capsules tid
Placebo dydrogesterone: placebo oral dydrogesterone 10 mg tablets tid</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemias NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Thrombocytopenias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Rate and rythm disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Autosomal chromosomal abnormalities</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Arterial disorders congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Cardiac septal defects congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Cardiac valve disorders congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Central nervous system disorders congenital NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Cerebral disorders congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Sex chromosomal abnormalities</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal and abdominal pains (excl oral and throat)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal and gastrointestinal infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>cytomegaloviral infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>infections NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>non-site specific injuries NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Non-site specific procedural complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Renal and urinary tract injuries NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Foetal and neonatal diagnostic procedures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>protein analyses NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Potassium imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Autonomic nervous system disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Neurological signs and symptoms NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Seizures and seizure disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>spontaneous abortion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="518"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>abortion not specified as induced or spontaneous</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="518"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>maternal complications of pregnancy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="518"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>labor onset and length abnormalities</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="518"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Still birth and foetal death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Foetal complications NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Hypertension associated disorders of pregnancy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Amniotic fluid and cavity disorders of pregnancy NEC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Gestational age and weight conditions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Haemorrhagic complications of pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>High risk pregnancies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Normal pregnancy, labour and delivery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Umbilical cord complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Abortion related conditions and complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>foetal growth complications</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>maternal complications of delivery NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Postpartum complications NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary abnormalities</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian and fallopian tube disorders NEC</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="518"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Cervix disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Ovarian and fallopian tube cysts and neoplasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Menstruation and uterine bleeding NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Reproductive tract disorders NEC (excl neoplasms)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Vulvovaginal disorders NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Induced abortions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="518"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Obstetric therapeutic procedures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral embolism and thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Vascular hypertensive disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>haemorrhages NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="518"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="518"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="46" subjects_affected="44" subjects_at_risk="518"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="511"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="518"/>
                <counts group_id="E2" events="33" subjects_affected="31" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="39" subjects_affected="38" subjects_at_risk="518"/>
                <counts group_id="E2" events="42" subjects_affected="41" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="518"/>
                <counts group_id="E2" events="36" subjects_affected="32" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy of unknown location</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="518"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="75" subjects_affected="61" subjects_at_risk="518"/>
                <counts group_id="E2" events="53" subjects_affected="45" subjects_at_risk="511"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least sixty (60) days prior to submitting or presenting a manuscript or other materials relating to the Study to a publisher, reviewer, or other outside persons, the Site shall provide to Sponsor a copy of all such manuscripts and materials, and allow sponsor sixty (60) days to review and comment on them.
If the Sponsor requests, the Site shall remove any Confidential Information (other than Study results) prior to submitting or presenting the materials.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Erik van Leeuwen MSc, PMP</name_or_title>
      <organization>Abbott</organization>
      <phone>+31294479241</phone>
      <email>erik.vanleeuwen@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

